Dasa (DASA3) posted net income of R$ 173 mn in the third quarter of 2026 (3Q26), up 78.7% from R$ 97 mn in 3Q25. On a comparable scope basis, which excludes operations sold or transferred to Rede Américas, 3Q25 was R$ 79 mn and growth was 120.0%. Consolidated gross revenue totaled R$ 2.6 bn (R$ 2,594 mn), down 9% from 3Q25 and up 8% on a comparable scope basis.
Consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) was R$ 640 mn, with a margin of 26.6%, down 1.7% on a comparable scope basis. Excluding equity income, EBITDA totaled R$ 617 mn, up 4.7%, with a margin of 25.6%. The consolidated gross margin was 31.9%, a reduction of 2.0 p.p. on a comparable scope basis, which the company attributes mainly to accounting reallocations between costs and expenses.
By segment, gross revenue from National Diagnostics was R$ 2,363 mn, up 7.6%, and Hospitals and Oncology Northeast totaled R$ 231 mn, up 7.1% on a comparable scope basis. In the first nine months of 2026, net income was R$ 148 mn, compared with a loss of R$ 187 mn in the same period of 2025. The net financial result was negative R$ 220 mn, an improvement of 39.5% over 3Q25 on a comparable scope basis.
Operating cash generation was R$ 456 mn and free cash flow was R$ 369 mn. Net financial debt after acquisitions payable and receivables prepayment stood at R$ 5.4 bn (R$ 5,435 mn), down R$ 188 mn from 2Q26. Leverage (net debt to EBITDA) was 2.76x under the current scope and 3.39x under the covenant criteria (contractual limits), below the 4.0x ceiling. In July, the company completed its 23rd debenture issuance, of R$ 700 mn, and early redeemed the 16th issuance.
The 50% stake in Rede Américas contributed R$ 23 mn in equity income in the quarter, compared with R$ 62 mn in 3Q25. The network posted net income of R$ 45 mn and EBITDA of R$ 420 mn in 3Q26.
